- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06132360
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
January 24, 2024 updated by: Ikaria Bioscience Pty Ltd
A Phase 1, Randomized, Single-blinded, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
This is a randomized, placebo-controlled, single ascending-dose (SAD) study of administered SC to adult subjects with elevated LDL-C.
Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Esther JIANG
- Phone Number: +8613916015172
- Email: esther.jiang@ronatherapeutics.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male and female subjects, aged 18 to 60 years, inclusive
- Body mass index between 18 and 32 kg/m2, inclusive, with body weight > 45 kg for females and >50 kg for males
- Serum LDL-C ≥100 mg/dL (2.6 mmol/L) at screening and Day -1
- Fasting triglycerides < 400 mg/dL (<4.52 mmol/L) at screening and Day -1
Exclusion Criteria:
- Known underlying disease or medical condition that may have a potential impact on general safety assessment, lipid metabolism, or glucose metabolism, or surgical condition (including, but not limited to, bariatric surgery) that, in the opinion of the investigator, may interfere with the interpretation of the results of the clinical study
- Received any medication including, but not limited to, statins, ezetimibe, or lipid-altering nutrients within 30 days prior to screening, or PCSK9 antibody within 90 days prior to screening, or any LDL-C-lowering siRNA therapy within 12 months prior to screening
- History of multiple drug allergies or allergic reactions to oligonucleotides or N-acetylglucosamine (GalNAc)
- Subjects with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 1.5 times the upper limit of normal (ULN) at the time of screening (one repeat of the screening assay is permitted) with clinically significant ALT and/or AST > ULN and ≤ 1.5 times the ULN as determined by the investigator
- Any medical condition that, in the opinion of the Investigator, makes the subject unsuitable for enrollment or may interfere with the subject's participation in or completion of the study. This includes, but is not limited to: history or presence of cardiovascular disease (including peripheral arterial and cerebrovascular disease); diabetes mellitus (except for diabetes mellitus of pregnancy in remission); cerebrovascular accidents; and abnormal thyroid function.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cohort 1
or placebo
|
This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C.
Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
|
Experimental: Cohort 2
or placebo
|
This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C.
Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
|
Experimental: Cohort 3
or placebo
|
This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C.
Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
|
Experimental: Cohort 4
or placebo
|
This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C.
Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety and tolerability of RN0191 administered as escalating single subcutaneous (SC) doses in adult subjects with elevated low-density lipoprotein-cholesterol (LDL-C)
Time Frame: For each subject in the study, the duration of the study clinic visits is approximately 18 weeks from screening to Day 85 EOS examination.
|
This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C.
Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
|
For each subject in the study, the duration of the study clinic visits is approximately 18 weeks from screening to Day 85 EOS examination.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 6, 2023
First Submitted That Met QC Criteria
November 13, 2023
First Posted (Actual)
November 15, 2023
Study Record Updates
Last Update Posted (Estimated)
January 26, 2024
Last Update Submitted That Met QC Criteria
January 24, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RN0191-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Reduce the LDL-C Level in Hypercholesteremia Patients
-
Ikaria Bioscience Pty LtdRecruitingTo Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other ComorbiditiesAustralia
-
Shanghai Tong Ren HospitalRecruitingTo Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive PatientsChina
-
Chun PanUnknownEvaluate the Correlation Between the Level of Mitochondrial DNA in Plasma and the Prognosis of the Patients With ARDS.China
-
Danish Procalcitonin Study GroupCompletedSepsis - to Reduce Mortality in the Intensive Care UnitDenmark
-
University of Buenos AiresNot yet recruitingTo Assess the Clinical Usefulness and Acceptability Level of the UP Online Group Format in Argentina as Well as Participants' SatisfactionArgentina
-
Boston Scientific CorporationActive, not recruitingThe Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial FibrillationDenmark
-
University of FoggiaCompletedThe Role of Valsalva Manoeuvre, in Thyroidectomy to Reduce Postoperative BleedingItaly
-
Yonsei UniversityWithdrawnPatients in the Treatment of Subjects With All-comer Who Are to Undergo PCI
-
All India Institute of Medical Sciences, BhubaneswarNot yet recruitingThe Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
-
University of Erlangen-Nürnberg Medical SchoolAOK Bayern; Federal Joint Committee; Friedrich-Alexander-Universität Erlangen-Nürnberg and other collaboratorsCompletedGeriatric Patients in the Transition From Hospital to HomeGermany
Clinical Trials on RN0191
-
Ikaria Bioscience Pty LtdRecruitingTo Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other ComorbiditiesAustralia